louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05383937: Comparative Impact of Protocolized Management, Intensive Rehabilitation Versus Long-term Classic Rehabilitation of Dyslexic Children.
Official title: Comparative Impact of Protocolized Management, Intensive Rehabilitation Versus Long-term Classic Rehabilitation of Dyslexic Children.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Dyslexia
Speech Therapy
Children, Only
Keywords: Dyslexia
Speech Therapy
Children
Intensive rehabilitation
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor class: OTHER
First posted: 2022-05-20
Enrollment: 3
Sex: ALL
Minimum age (years): 8
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Dyslexia is characterized by difficulties with accurate and/or fluent word recognition and by poor spelling and decoding abilities. In France, dyslexia is a public health disorder. Dyslexia is a real public health problem in France, affecting 6% of the general population. However, no clinical trial of a standardized rehabilitation has shown an impact on reading fluency. In the era of intensive rehabilitation, a new protocol based on the current data from the medical literature has been designed.


Eligibility criteria: Inclusion Criteria:

* Children from 8 to 12 years old,
* Living in and around 50 kilometers from Besançon.
* Diagnosis of dyslexia according to the DSM-V or CIM-10 requirements.
* Consent form signed by the parental authority and the child,
* Affiliation to a social security system.

Exclusion Criteria:

* Mother's medical history of pregnancy or delivery complications,
* Patients's medical history of neurological infectious, vascular or tumoral events,
* Patient's medical history of intellectual deficiency,
* Patients's medical history of visual or hearing disorders,
* Patient's medical history of psychiatric disorders (especially diagnosis of Attention Deficit / Hyperactivity Disorders (AD/HD)),
* legal incapacity,
* limited cooperation suspected by the investigator.

Primary outcomes:
measure: Reading fluency to the Alouette test.
timeFrame: Six month.
Secondary outcomes:
measure: Phonological processing tests.
timeFrame: Six month.
measure: Visual pattern.
timeFrame: Six month.
measure: Life Quality.
timeFrame: 6 month.
measure: Rehabilitation adhesion.
timeFrame: 6 month
measure: Speech langage rehabilitation cost.
timeFrame: 6 month.
measure: Family and school evaluation.
timeFrame: 6 month.
Other outcomes:
Locations:
city: Besançon
country: France
facility: CHU de besançon
Study officials:
affiliation: CHU de Besançon
name: Julien BEVALOT
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01043237: Frequency Analysis of Coronary Artery Disease
Official title: A Single-centered Investigation Into the Frequency Domain Patterns in Vessels of Patients With Coronary Artery Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Disease
Keywords: acoustic
digital
sound
vibration
coronary
auscultation
artery
diagnosis
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2010-01-06
Enrollment: 330
Sex: ALL
Minimum age (years): 18
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients presenting to the University of Minnesota Medical Center (UMMC) Fairview Clinics, Physicians (UMP) or the Redwing, Minnesota clinic

Brief summary: The purpose of this study is to determine if coronary artery disease can be detected using an electronic, acoustic recording instrument. The presence or absence of abnormal pathology will be confirmed by diagnostic angiography as part of the normal patient care at this institution.


Eligibility criteria: Inclusion Criteria:

* Patients aged 18-89 years old and recommended for a cardiology related angiogram within 24 hours

Exclusion Criteria:

* Any patient less than 18 years of age or greater than 89 years of age.
* Any patient with any of the following conditions: pregnant or nursing, prior myocardial infarction, left ventricular device, heart transplant, valve replacement, congestive heart failure, atrial fibrillation (non-intermittent), endocarditis or any heart viral or bacterial infection, any patient who has or requires medication or other heart rhythm altering treatment.

Primary outcomes:
measure: to determine if coronary artery disease can be detected using an electronic, acoustic recording instrument
timeFrame: Baselin
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota Medical Center (UMMC) Fairview Clinics
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: Robert Wilson, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04301037: Tension Band Wiring Versus Cannulated Screws in Fixation of Medial Malleolus in Ankle Fracture
Official title: Tension Band Wiring Versus Cannulated Screws in Fixation of Medial Malleolus in Ankle Fracture: Randomized Comparative Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Medial Malleolus Fracture
Keywords: Fixation of medial malleolus
Tension band
Malleolus fracture
Ankle fracture
Lead sponsor: Hawler Medical University
Sponsor class: OTHER
First posted: 2020-03-09
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a prospective randomized study conducted on 30 patients with an age spanning between 20 and 55 years. Half of the sample was treated by tension band wiring for closed medial malleolar fractures, and the other half by two cannulated screws. The patients were assessed at (6w-3months and 6months) for clinical and radiological union and evaluated functionally (12 months) using modified Olerund and Molander scoring system.


Eligibility criteria: Inclusion Criteria:

1. Patients aged from 20-55 years.
2. Isolated or bimalleolar ankle fractures.
3. Closed fractures.

Exclusion Criteria:

1. Patient with poor bone quality on x ray (radiological osteopenia, thinning of the cortices, loss of trabecular definitions and previous insufficiency fractures)
2. Type D isolated medial malleolus, supination adduction (vertical malleolar) fractures.
3. Comminuted fractures.
4. Skeletally immature patients.

Primary outcomes:
measure: Modified Olerund and Molander scoring system
timeFrame: The functional outcome was measured in all patient 12 months after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Erbil
country: Iraq
facility: Sherwan Hamawandi
Study officials:
References:
Clinical trial NCT01737437: Effect of Lidocaine Sprayed on Hemodynamics During Endotracheal Intubation
Official title: Effect of Lidocaine Sprayed on Direct Laryngoscopy and Trachea on Hemodynamics During Endotracheal Intubation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Neurosurgical Patients
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2012-11-29
Enrollment: 80
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: A previous study demonstrated topical lidocaine spray on the larynx and the trachea is effective in reducing hemodynamic response to laryngoscopy and endotracheal intubation. In clinical practice, blind oropharyngeal application of lidocaine without aiding direct laryngoscopy can not assured that sprayed lidocaine effectively reaches the larynx and trachea. Therefore, direct laryngoscopy should be necessary to reach topical lidocaine to correct sites. Unfortunately, direct laryngoscopy itself can affect hemodynamics during spraying lidocaine. In this study, we will investigate an effect of lidocaine sprayed on direct laryngoscopy and the tracheal mucosa on hemodynamic change throughout intubation.


Eligibility criteria: Inclusion Criteria:

* aged 20-60 years,
* ASA groups I or II

Exclusion Criteria:

* ASA III or IV,
* hypertension,
* anticipated difficult airway, and
* severe coronary and cerebrovascular diseases

Primary outcomes:
measure: mean blood pressure, heart rate
timeFrame: baseline, at laryngoscope insertion, 60s after laryngoscope insertion, during intubation, one, two, three min after endotracheal intubation
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References:
Clinical trial NCT02865837: Effect of Bladder Distension on Dosimetry in Brachytherapy of Cervical Cancer
Official title: Effect of Bladder Distension on Organs at Risk Doses in PDR 3D Image-guided Brachytherapy of Cervical Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cervical Cancer
Keywords: Brachytherapy
Organs at Risk
Bladder volume
Cervical cancer
Lead sponsor: Institut de Cancérologie de Lorraine
Sponsor class: OTHER
First posted: 2016-08-15
Enrollment: 22
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The purpose of this study is to compare, for each patient, dosimetry of organs at risk (bladder, rectum, sigmoid, small bowel) in two bladder distension procedures (emptied by a urinary catheter or filled with 120cc) during PDR 3D image-guided brachytherapy of cervical cancer.


Eligibility criteria: Inclusion Criteria:

* Age \> or = 18 years old
* with a cervical cancer histologically proven (squamous cell carcinoma, adenocarcinoma and neuroendocrine cell carcinoma)
* Utero-vaginal brachytherapy indications::

  * Stage 1B1: brachytherapy before surgery
  * Stages IB2 to IIIB: after pelvic radiotherapy (45Gy/25 fractions/5 weeks) with or without concomitant chemotherapy
* Ability to provide an informed written consent form
* Patient must be affiliated to a social security system

Exclusion Criteria:

* Age \< 18 years old
* History of pelvic radiotherapy
* History of pelvic surgery
* Recent joint prothesis (\<3 months)
* Pregnant woman or being breastfeeding
* Patients deprived of liberty or under supervision

Primary outcomes:
measure: Demonstrate the non inferiority of 3D image-guided brachytherapy with emptied bladder compared to filled bladder for the dose received by the bladder
timeFrame: 1 day
Secondary outcomes:
measure: Non-inferiority based on the dose received by the rectum
timeFrame: 1 day
measure: Non-inferiority based on the dose received by the sigmoid
timeFrame: 1 day
measure: Non-inferiority based on the dose received by the small bowel
timeFrame: 1 day
measure: FIGO staging system
timeFrame: 1 day
measure: Body Mass Index
timeFrame: 1 day
Other outcomes:
Locations:
city: Vandoeuvre-lès-Nancy
country: France
facility: Institut de Cancérologie de Lorraine
Study officials:
affiliation: Institut de Cancérologie de Lorraine
name: RENARD OLDRINI SOPHIE, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00889837: Staccato Loxapine Pulmonary Safety in Patients With COPD
Official title: Pulmonary Safety of Staccato® Loxapine for Inhalation in Subjects With Chronic Obstructive Pulmonary Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Chronic Obstructive Pulmonary Disease
Keywords: Staccato Loxapine
COPD
pulmonary safety
Lead sponsor: Alexza Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2009-04-29
Enrollment: 53
Sex: ALL
Minimum age (years): 40
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the pulmonary safety of 2 doses of Staccato Loxapine within a day in patients with COPD.

Detailed description: To address the possibility that inhalation of loxapine may have adverse pulmonary effects, we studied two 10-mg inhaled doses of loxapine or placebo were given 10 hr apart to subjects with chronic obstructive pulmonary disease (COPD). The objective was to determine the time course and reversibility of pulmonary effects for inhaled loxapine compared with placebo.

Eligibility criteria: Inclusion Criteria:

* History of COPD for at least 6 months with pre-bronchodilator FEV1 ≥40% of predicted value and \>15 pack-year history of cigarette smoking.

Exclusion Criteria:

* History of asthma, or any other acute or chronic pulmonary disease.

Primary outcomes:
measure: Change in FEV1 from baseline by spirometry
timeFrame: at each post-treatment time point (15 min to 34 hr)
Secondary outcomes:
measure: Change in FVC from baseline by spirometry
timeFrame: at each post-treatment time point (15 min to 34 hr)
measure: Treatment emergent adverse events
timeFrame: Post-treatment time points
Other outcomes:
Locations:
city: Spartanburg
country: United States
facility: Spartanburg Medical Research
state: South Carolina
Study officials:
affiliation: Alexza Pharmaceuticals, Inc.
name: Mildred D. Gottwald, PharmD
role: STUDY_DIRECTOR
References:
citation: Gross N, Greos LS, Meltzer EO, Spangenthal S, Fishman RS, Spyker DA, Cassella JV. Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials. J Aerosol Med Pulm Drug Deliv. 2014 Dec;27(6):478-87. doi: 10.1089/jamp.2013.1114.
Clinical trial NCT00885937: Comparative Safety Study of New Sinecort Formulation Versus Positive Control
Official title: Single-blind, Randomized, Controlled, Single Center Trial to Evaluate the Skin Irritation Potential of a New Topical Formulation by Means of an Occlusive Patch Test in Healthy Subjects.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Dexpanthenol
Safety,
New formulation
Topical administration
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2009-04-22
Enrollment: 33
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study is focused to prove a favorable safety profile of the new formulation.


Eligibility criteria: Inclusion Criteria:

* Age of at least 18 years
* Skin type I, II, or III according to Fitzpatrick
* Subjects of childbearing potential must use an acceptable method of contraception. Hormonal or oral contraceptive drugs, intra-uterine devices (IUD) and abstinence are considered acceptable methods of contraception.

Exclusion Criteria:

* Clinical history suggestive of intolerance, allergies or idiosyncrasies to one of the products or the ingredients of the products including the patch.
* Known skin allergies.
* Dermatologic diseases that might interfere with the evaluation of test site reaction.
* Other(s), considered as important by the investigator (e.g. multiple birth marks in the test area, important hair growth in the test area, pigmented or extremely suntanned skin impairing visual assessment, tattoos in the test area.
* Topical use of any cosmetic preparation on the test areas within 5 days prior to Day 1 (Start of Treatment) or during the trial
* Within 3 weeks prior to Day 1 and during the entire trial. Any systemic or topical medication likely to interfere with the trial purposes: e.g. immune-modulating therapy (e.g. corticosteroids, cytotoxics or immunosuppressants) and any dermatological medication (drug or medical device.
* Within 1 week prior to Day 1 and during the entire trial any medication with common effects on the perfusion of skin vessels (e.g. vasodilators or vasoconstrictors, ß-receptor blocking drugs, antihistamines) should not be used.

Primary outcomes:
measure: Irritation rate
timeFrame: After 21 applications
Secondary outcomes:
measure: Irritation potential
timeFrame: After 21 applications
Other outcomes:
Locations:
city: Münster
country: Germany
state: Nordrhein-Westfalen
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT02981537: Two-staged Approach in Positioning Endobronchial Blockers Without Fiberoptic Guidance
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: One-lung Ventilation
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2016-12-05
Enrollment: 94
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to find a novel method for placing endobronchial blockers without fiberoptic guidance to provide one-lung isolation during anesthesia for thoracic surgery.


Eligibility criteria: Inclusion Criteria:

* patients scheduled for lung resection

Exclusion Criteria:

* refuse to enroll
* patients with lesions involving mainstem bronchi
* patients with anomalies in tracheobronchial tree

Primary outcomes:
measure: location of endobronchial blocker
timeFrame: immediately after the insertion of blocker by fiberoptic bronchoscope
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: JH Bahk
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06937437: Effects of Tele Speech Therapy on the Treatment of Stammering in Adults Who Stutter
Official title: Effects of Tele Speech Therapy on the Treatment of Stammering in Adults Who Stutter
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Stammering
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2025-04-22
Enrollment: 16
Sex: ALL
Minimum age (years): 15
Maximum age (years): 40
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the study is to determine the effectiveness of telespeech therapy on the treatment of stammering.


Eligibility criteria: Inclusion Criteria:

* Both Genders
* Adults With stuttering 15 to 40 years according to WHO criteria

Exclusion Criteria:

- Stammering with any comorbid are excluded eg. Visual and Hearing Impairment

Primary outcomes:
measure: Stuttering Severity Instrument - Fourth Edition (SSI4)
timeFrame: Base line and 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Muaz Medical Complex
state: Punjab
Study officials:
affiliation: Riphah International University
name: Mamona Riaz, M.S
role: PRINCIPAL_INVESTIGATOR
References:
citation: Månsson H. Childhood stuttering: Incidence and development. Journal of fluency disorders. 2000;25(1):47-57.
citation: Eslami Jahromi M, Ahmadian L, Bahaadinbeigy K. The effect of tele-speech therapy on treatment of stuttering. Disabil Rehabil Assist Technol. 2022 Jan;17(1):34-39. doi: 10.1080/17483107.2020.1754475. Epub 2020 Apr 17.
Clinical trial NCT06914115: Effect of Transcutaneous Auricular Nerve Stimulation vs Body Rocking Exercises on Spasticity of Upper Limb
Official title: Effect of Transcutaneous Auricular Nerve Stimulation vs Body Rocking Exercises on Spasticity of Upper Limb in Young Stroke Patients
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Spasticity, Muscle
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2025-04-06
Enrollment: 42
Sex: ALL
Minimum age (years): 35
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The primary aim of this study is to compare the effect of TANS and body rocking exercises on reducing upper limb spasticity in young stroke patients( under 50). Specific objectives include evaluating changes in muscle tone, motor function, pain reduction, and functional independence following each intervention.

Detailed description: This randomized controlled trial, RCT, will involve 42 young stroke patients with upper limb spasticity randomly assigned to three groups, transcutaneous auricular nerve stimulation, body rocking exercise, or control group, usually rehabilitation. Participants will receive 30-minute transcutaneous nerve stimulation session or 20 to 30-minute body rocking exercise in session 3 to 4 times a week over an 8-week period. Key outcome measures include the Modified Ashworth Scale for Spasticity, the Fusel-Meyer Assessment for Motor Function, the Numeric Rating Scale for Pain, and Stroke Impact Scale for Functional Independence.

Eligibility criteria: Inclusion Criteria:

* Age 35-50 years
* Diagnosed with stroke (ischemic or hemorrhagic)
* Upper limb spasticity (Modified Ashworth Scale score ≥1)
* Post-stroke duration of ≥3 months
* Able to follow verbal and physical instructions
* No contraindications to electrical stimulation or exercise therapy

Exclusion Criteria:

* Severe cognitive impairment or communication disorders
* History of epilepsy or uncontrolled seizures
* Pacemaker or implanted medical devices
* Severe cardiac, orthopedic, or neurological conditions
* Uncontrolled hypertension or diabetes
* Participation in another spasticity-related trial

Primary outcomes:
measure: Modified Ashworth Scale (MAS)
timeFrame: 12 Months
measure: Fugl-Meyer Assessment (FMA)
timeFrame: 12 Months
measure: Numeric Rating Scale (NRS)
timeFrame: 12 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Okāra
country: Pakistan
facility: City Rehabilitation Center
state: Sindh
Study officials:
References: